Last reviewed · How we verify
ELIGARD 22.5mg
At a glance
| Generic name | ELIGARD 22.5mg |
|---|---|
| Also known as | ELIGARD |
| Sponsor | Ontario Clinical Oncology Group (OCOG) |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC) (PHASE2)
- A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer (PHASE2)
- The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's (PHASE2)
- Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer (PHASE2)
- GP Extended Action Triptorelin (PHASE4)
- Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients (PHASE2)
- REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer (PHASE2)
- Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ELIGARD 22.5mg CI brief — competitive landscape report
- ELIGARD 22.5mg updates RSS · CI watch RSS
- Ontario Clinical Oncology Group (OCOG) portfolio CI